| Trial ID: | L5709 |
| Source ID: | NCT00761852
|
| Associated Drug: |
Ruboxistaurin
|
| Title: |
Signaling Mechanisms and Vascular Function in Diabetes Mellitus
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Type 1 Diabetes Mellitus|Type 2 Diabetes Mellitus
|
| Interventions: |
DRUG: Ruboxistaurin|DRUG: Placebo
|
| Outcome Measures: |
Primary: To test the hypothesis that activation of protein kinase Cß (PKCß) impairs vascular reactivity in patients with diabetes mellitus, one testing visit every 4 weeks for 8 weeks |
|
| Sponsor/Collaborators: |
Sponsor: Brigham and Women's Hospital | Collaborators: Eli Lilly and Company
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE2|PHASE3
|
| Enrollment: |
30
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: BASIC_SCIENCE
|
| Start Date: |
1999-05
|
| Completion Date: |
2007-10
|
| Results First Posted: |
|
| Last Update Posted: |
2008-09-30
|
| Locations: |
|
| URL: |
https://clinicaltrials.gov/show/NCT00761852
|
